Print Memorial Sloan Kettering gynecologic oncologist and surgeon Carol Brown speaks with children at a community health fair in Harlem.
Memorial Sloan Kettering offers an array of programs designed for a wide audience of patients, their families, caregivers, and community members. These programs help to educate the public about cancer-related topics such as prevention, screening, and treatment. In addition to Memorial Sloan Kettering Cancer Center’s institutional initiatives, our physicians, nurses, and other staff members frequently volunteer their time and cancer expertise in partnership with other organizations in the community.
Our Office of Community Affairs also provides our local community members with up-to-date information about activities at Memorial Sloan Kettering that may be of interest.
NYC cancer center staff underpaid to clean COVID areas: suit nydailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nydailynews.com Daily Mail and Mail on Sunday newspapers.
Jan. 8, 2021 10:55 am ET
A 65-year-old man was arrested Thursday night after firing a gun at police officers at Memorial Sloan Kettering Cancer Center in Manhattan and then barricading himself in a bathroom, New York Police Department officials said.
The officials said Joseph Gill, 65 years old, of Manhattan, went to the renowned facility on Thursday night, seeking treatment for an unspecified ailment. Mr. Gill became agitated and displayed a handgun upon examination by a nurse, according to the officials.
Mr. Gill subsequently fired two shots at two NYPD officers and discharged additional rounds from his weapon in the presence of hospital staff and patients, the officials said. Mr. Gill then barricaded himself in a bathroom, according to the officials.
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson s Disease
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 7, 2021 /PRNewswire/ BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to proceed with a Phase 1 (Ph1) study in patients with advanced Parkinson s disease (PD). This is the first trial in the United States to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson s disease. Under the IND, BlueRock and MSK will execute a Ph1 clinical trial to evaluate the safety, tolerability and preliminary efficacy of DA01 in patients with PD.